DMS Pharmaceutical Group Inc.

DMS Pharmaceutical Group Inc., a woman-owned small business headquartered in Park Ridge, Illinois, supplies branded and generic prescription drugs, biologics, over-the-counter medications, vaccines, and medical consumables to the Department of Defense as a prime contractor under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V).

DMS Pharmaceutical operates exclusively as a prime contractor, holding a single-award indefinite delivery contract (SPE2DX) awarded by the Defense Logistics Agency on November 13, 2025, with a $499.999 billion ceiling and an ultimate completion date of December 31, 2036. The company is the sole regional prime vendor within PPV-G GEN V's $30.3 billion acquisition strategy, authorized to issue firm fixed-price delivery orders for pharmaceutical products and medical consumables supporting Department of Defense military healthcare facilities worldwide, including domestic and overseas locations. Place of performance is Park Ridge, Illinois. PPV-G GEN V is structured with a 30-month base period and three 30-month option periods. The source reveals no set-aside designation on the underlying IDC; DMS Pharmaceutical competes on full-and-open terms.

DMS Pharmaceutical's customer concentration is extreme and monolithic. The Defense Logistics Agency Troop Support Medical accounts for 322,544 awards (86% of all awards in the source) with $107.8 billion in combined potential value, and the Defense Logistics Agency proper accounts for 52,700 additional awards worth $47.6 billion. Together, DLA customer components represent the entirety of the vendor's meaningful federal footprint—$155.4 billion of the $175.55 billion combined potential value—with small amounts of work routed to Department of Veterans Affairs regional networks. This concentration reflects DMS Pharmaceutical's positioning as a specialized pharmaceutical distributor to military healthcare operations.

Recent activity shows deliveries of high-value branded oncology and specialty pharmaceutical products under PPV-G GEN V, including Keytruda (various formulations), Botox, Xolair, Nexplanon, Stelara, Mirena, and Kyleena, as well as lower-value generic and over-the-counter medications. Individual delivery orders range from single-digit dollar amounts to six-figure ceiling values (e.g., $150,995 for a single pharmaceutical bundle order on April 15, 2026). The vendor's award volume is extraordinarily high—376,081 total awards in the source spanning 2003 to April 2026—reflecting the transactional nature of pharmaceutical supply ordering. Year-over-year data from 2022–2026 shows relative stability around 36,000–40,000 awards annually, with 2026 showing only partial-year data (11,979 awards through mid-April).

The top five parent vehicles are all DLA indefinite delivery contracts under the PPV-G GEN V framework: SPE2DX15D9383 (61,520 task orders, $80.7 million combined potential value), SPE2DX15D9905 (20,016 task orders, $25.9 million), SPE2DX15D9901 (16,070 task orders, $63.9 million), SPE2DX15D9628 (12,043 task orders, $66.7 million), and SPE2DX16D9991 (9,959 task orders, $4.8 million). Recompete exposure in the next twenty-four months is minimal—only one award with a $248 thousand combined potential value reaches ultimate completion in that window, reflecting the long-term nature of the underlying PPV-G GEN V IDC running through 2036.

NAICS concentration aligns with pharmaceutical distribution: 189,985 awards fall under Drugs and Druggists' Sundries Merchant Wholesalers (NAICS 424210), 116,486 under Medicinal and Botanical Manufacturing, and 64,224 under Pharmaceutical Preparation Manufacturing. PSC coding is dominated by Drugs and Biologicals (344,670 awards), with smaller volumes in Medical and Surgical Instruments, Equipment, and Supplies. Combined dollars obligated across all awards total $2.66 billion, representing only 2% of the $175.55 billion combined potential value, indicating that most awards remain unfilled and reflect the ongoing nature of the pharmaceutical supply contract.

DMS is a full-line, woman-owned pharmaceutical wholesaler serving the brand and generic drug needs of nationwide customers: hospitals, closed pharmacies, long-term care facilities, and surgery centers.